Westenberg H - Search Results

1

Adjunctive quetiapine for serotonin reuptake inhibitor-resistant obsessive-compulsive disorder: a meta-analysis of randomized controlled treatment trials.

Fineberg NA, Stein DJ, Premkumar P, Carey P, Sivakumaran T, Vythilingum B, Seedat S, Westenberg H, Denys D. Fineberg NA, et al. Among authors: westenberg h. Int Clin Psychopharmacol. 2006 Nov;21(6):337-43. doi: 10.1097/01.yic.0000215083.57801.11. Int Clin Psychopharmacol. 2006. PMID: 17012980

2

Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment-refractory obsessive-compulsive disorder: an open-label study.

Denys D, van Megen H, Westenberg H. Denys D, et al. Among authors: westenberg h. J Clin Psychiatry. 2002 Aug;63(8):700-3. doi: 10.4088/jcp.v63n0807. J Clin Psychiatry. 2002. PMID: 12197450 Clinical Trial.

3

A score for predicting response to pharmacotherapy in obsessive-compulsive disorder.

Denys D, Burger H, van Megen H, de Geus F, Westenberg H. Denys D, et al. Among authors: westenberg h. Int Clin Psychopharmacol. 2003 Nov;18(6):315-22. doi: 10.1097/00004850-200311000-00002. Int Clin Psychopharmacol. 2003. PMID: 14571151 Clinical Trial.

4

A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder.

Denys D, van der Wee N, van Megen HJ, Westenberg HG. Denys D, et al. J Clin Psychopharmacol. 2003 Dec;23(6):568-75. doi: 10.1097/01.jcp.0000095342.32154.54. J Clin Psychopharmacol. 2003. PMID: 14624187 Clinical Trial.

5

Female hormones affect symptom severity in obsessive-compulsive disorder.

Vulink NC, Denys D, Bus L, Westenberg HG. Vulink NC, et al. Int Clin Psychopharmacol. 2006 May;21(3):171-5. doi: 10.1097/01.yic.0000199454.62423.99. Int Clin Psychopharmacol. 2006. PMID: 16528139

6

Effects of quetiapine on cognitive functioning in obsessive-compulsive disorder.

de Geus F, Denys D, Westenberg HG. de Geus F, et al. Int Clin Psychopharmacol. 2007 Mar;22(2):77-84. doi: 10.1097/YIC.0b013e32801182f7. Int Clin Psychopharmacol. 2007. PMID: 17293707 Clinical Trial.

7

The adequacy of pharmacotherapy in outpatients with obsessive-compulsive disorder.

Denys D, Van Megen H, Westenberg H. Denys D, et al. Among authors: westenberg h. Int Clin Psychopharmacol. 2002 May;17(3):109-14. doi: 10.1097/00004850-200205000-00003. Int Clin Psychopharmacol. 2002. PMID: 11981351

8

Emerging skin-picking behaviour after serotonin reuptake inhibitor-treatment in patients with obsessive-compulsive disorder: possible mechanisms and implications for clinical care.

Denys D, van Megen HJ, Westenberg HG. Denys D, et al. J Psychopharmacol. 2003 Mar;17(1):127-9. doi: 10.1177/0269881103017001718. J Psychopharmacol. 2003. PMID: 12680750

9

A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder.

Westenberg HG, Stein DJ, Yang H, Li D, Barbato LM. Westenberg HG, et al. J Clin Psychopharmacol. 2004 Feb;24(1):49-55. doi: 10.1097/01.jcp.0000104906.75206.8b. J Clin Psychopharmacol. 2004. PMID: 14709947 Clinical Trial.

10

Synergistic dopamine increase in the rat prefrontal cortex with the combination of quetiapine and fluvoxamine.

Denys D, Klompmakers AA, Westenberg HG. Denys D, et al. Psychopharmacology (Berl). 2004 Nov;176(2):195-203. doi: 10.1007/s00213-004-1880-0. Epub 2004 May 11. Psychopharmacology (Berl). 2004. PMID: 15138756

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

252 results

Search Page

Filters